Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 AG-348 versus placebo in adults with pyruvate kinase deficiency who are not regularly transfused
NL-OMON48591Phase 3Active, not recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pyruvate kinase deficiency (PKD) comparing Mitapivat with Placebo (2 arms). Primary endpoint: Hemoglobin response. Started Feb 2019; status: active, not recruiting.
02
Drugs
mitapivat
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on NL-OMON48591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48591.